308 related articles for article (PubMed ID: 26861063)
1. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.
Hong X; Li F; Tang K; Pang S; Lin G; Li S; Bao J; Tan W
Int Urol Nephrol; 2016 Jun; 48(6):967-75. PubMed ID: 26861063
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
5. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
8. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA.
Manley BJ; Kim EH; Vetter JM; Potretzke AM; Strope SA
Int Braz J Urol; 2017; 43(3):432-439. PubMed ID: 28128914
[TBL] [Abstract][Full Text] [Related]
9. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
10. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis.
Chen B; Li J; Huang Y; Tang B; Jiang J; Chen Z; Li J; Wang P; Cao D; Liu L; Wei Q
Int J Surg; 2023 Apr; 109(4):982-994. PubMed ID: 36974696
[TBL] [Abstract][Full Text] [Related]
11. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
12. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
13. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
14. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
[TBL] [Abstract][Full Text] [Related]
15. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.
Kim SH; Kim JK; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
Oncotarget; 2017 Jul; 8(30):49615-49624. PubMed ID: 28548948
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
[TBL] [Abstract][Full Text] [Related]
19. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
[TBL] [Abstract][Full Text] [Related]
20. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
